Sunshine Biopharma Soars 45% on Revenue Surge, Drug Approval

Sunshine Biopharma's stock price surged to $42.31 in pre-market trading on April 2, 2025, reflecting a significant increase in investor confidence.

Sunshine Biopharma reported a substantial increase in revenue for fiscal 2024, reaching $34.9 million, a 45% jump from the previous year's $24.1 million. This growth was driven by the successful launch of 13 new generic prescription drugs and the completion of a $10 million public offering to expand sales operations.

The company also received regulatory approval from Health Canada for its oncology drug NIOPEG®, a biosimilar of NEULASTA®. Additionally, Sunshine Biopharma announced groundbreaking research results in the Journal of Medicinal Chemistry, demonstrating the superior efficacy of its new Coronavirus PLpro inhibitor. This study showcases a PLpro inhibitor with sub-micromolar potency and robust in vivo efficacy in a mouse model of SARS-CoV-2 infection.

Furthermore, the company completed mouse model studies providing proof-of-concept for its K1.1 mRNA Lipid Nanoparticle as a novel therapeutic agent for human hepatocellular carcinoma. This development is significant as hepatocellular carcinoma is the third leading cause of cancer-related deaths worldwide.

Dr. Steve Slilaty, CEO of Sunshine Biopharma, expressed optimism about the company's future, stating, "We are pleased with our accomplishments in 2024, as we remain committed to reaching profitability in the near future. Looking ahead, we are excited about the opportunities for growth in 2025 and beyond, as we continue to advance our proprietary drug development program to deliver more life-saving medicines to the market."